Navigation Links
EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
Date:6/4/2013

Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients. In order to improve the outcome for these patients, EORTC trial 40091 BOS 2 will test the efficacy of adding bevacizumab or panitumumab to the standard treatment, peri-operative FOLFOX 4 chemotherapy.

Bevacizumab is a monoclonal antibody which targets the vascular endothelial growth factor (VEGF), and blocking VEGF could deprive the cancer of required nutrients. Panitumumab targets the epidermal growth factor receptor (EGFR). EGFR gene expression is upregulated in approximately 60 to 80% of CRC cases, and this has been linked to poor survival.

Dr. Bernard Nordlinger, CHU Ambroise Pare AP-HP, Boulogne-Billancourt and Coordinator of this study, says "The objective of this trial is to determine a new standard of care for these patients." The randomized phase 2 EORTC trial will investigate if treatment with perioperative modified FOLFOX6 plus either bevacizumab or panitumumab improves progression-free survival and pathological response in patients with up to eight resectable liver metastases resulting from wild type KRAS CRC as compared to treatment with perioperative modified FOLFOX 6 alone.

Dr. Stephane Benoist, Assistance Publique, Hpitaux de Paris, Hopital De Bicetre AP-HP, Le Kremlin Bicetre and co-Coordinator of this study, says "Following the EPOC study, perioperative FOLFOX chemotherapy became the new standard of care in many countries for patients with resectable colorectal liver metastases. Nevertheless, most patients developed recurrence despite perioperative FOLFOX chemotherapy. One of the ways to improve long term prognosis is to intensify the perioperative chemotherapy. The BOS 2 study addresses a major clinical question: is there any benefit from intensifying perioperative FOLFOX chemotherapy by adding biological therapy? Translational research projects that are part of this study will determine, for the first time, whether pathological response to preoperative chemotherapy could be a predictor of progression-free survival in resected patients, whether assessment of metabolic response by FDG-PET/CT after one course of chemotherapy could be an early predictor of no response, and whether biological subgroups in wild type KRAS patients would benefit more from one of the regimens. Overall, the BOS 2 study should be an important step towards improving the therapeutic management and long term prognosis of patients with resectable colorectal liver metastases."


'/>"/>
Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
2. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
3. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
4. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
5. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
6. New Hepatitis C Clinical Trial Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting M/F Patients with Hep C Age 18-65
7. Low Back Pain Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with Chronic Low Back Pain Age 18-80
8. DePuy ASR Hip Implant Lawyers at Wright & Schulte LLC Pleased with Judge’s Decision to Uphold $8.3 Million Award in California DePuy ASR Hip Lawsuit Trial
9. True-Dose Pets Launches New Trial-Sized Product Line
10. Vaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Pretrial Order in Federal Transvaginal Mesh Litigation
11. CureLauncher Introduces Personalized Clinical Trial Matching Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples ... the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare ... Center is an exciting addition to our provider network, and the addition will ...
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting ... Challenge , the Cradle to Cradle Products Innovation Institute has announced. , ... run through early 2018. The challenges are presented by the Institute in partnership with ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Neil H. Greco ... planning assistance to communities throughout the region, is launching a charity drive to raise ... is by far the deadliest killer in America, and is responsible for 1 in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017 North America ... GlobalData,s new report, "North America Insulin Delivery Market Outlook ... America Insulin Delivery market. The report provides value, in ... prices (USD) within market segments - Insulin Pens, Insulin ... The report also provides company shares and distribution shares ...
(Date:1/17/2017)... 2017 Research and Markets has announced ... - 2024" report to their offering. ... This new report revisits the market ... was issued in May of 2015. Self-healing is an area of ... analysis we projected a market potential of $2.7 billion ($US) by ...
(Date:1/17/2017)... Israel , January 17, 2017 Management ... TyrNovo, Ltd.   KIT-302 Development On Track For ... FDA in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; ... update call on Monday, January 23 rd at 8:30am Eastern Time to ...
Breaking Medicine Technology: